LNK/SH2B3基因改变在骨髓增殖性肿瘤及其他血液系统疾病中的作用
本文综述LNK/SH2B3基因在正常造血中的调控功能、已报道的SH2B3突变类型及其在骨髓增殖性肿瘤、淋系白血病和非恶性血液病中的作用,讨论这些遗传变异如何影响疾病发生发展,以及靶向LNK分子用于个体化诊疗的潜力。
要点
- LNK/SH2B3基因编码的抑制性衔接蛋白LNK是正常造血的关键调控因子。
- SH2B3的获得性或遗传性变异见于MPN、淋系白血病及非恶性血液病。
- 理解LNK变异对蛋白功能及驱动突变的影响有助于关联基因型与临床表型。
核心结论
- LNK/SH2B3基因的获得性或遗传性变异在骨髓增殖性肿瘤、淋系白血病和非恶性血液病中均有报道,理解这些变异对LNK蛋白功能及驱动突变的影响可能有助于关联患者基因型与表型并开发靶向该分子的治疗策略。
研究设计与样本
- 综述,总结LNK在正常造血中的功能、迄今报道的SH2B3突变及其对血液系统恶性肿瘤发生的影响,未报告检索范围。
主要发现
- 经典骨髓增殖性肿瘤的驱动突变靶向细胞因子受体/Janus激酶2(JAK2)通路并决定MPN表型,其他附加突变主要影响基因表达调控(表观遗传或剪接调节因子)和信号传导。
- 除体细胞突变外,胚系易感性(单核苷酸多态性和单倍型)可能强烈影响MPN的发生。
- LNK/SH2B3基因编码的抑制性衔接蛋白LNK是多种获得性或遗传性变异的靶点,这些变异见于MPN、淋系白血病和非恶性血液病。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Malignant hematological diseases are mainly because of the occurrence of molecular abnormalities leading to the deregulation of signaling pathways essential for precise cell behavior. High-resolution genome analysis using microarray and large-scale sequencing have helped identify several important acquired gene mutations that are responsible for such signaling deregulations across different hematological malignancies. In particular, the genetic landscape of classical myeloproliferative neoplasms (MPNs) has been in large part completed with the identification of driver mutations (targeting the cytokine receptor/Janus-activated kinase 2 (JAK2) pathway) that determine MPN phenotype, as well as additional mutations mainly affecting the regulation of gene expression (epigenetics or splicing regulators) and signaling. At present, most efforts concentrate in understanding how all these genetic alterations intertwine together to influence disease evolution and/or dictate clinical phenotype in order to use them to personalize diagnostic and clinical care. However, it is now evident that factors other than somatic mutations also play an important role in MPN disease initiation and progression, among which germline predisposition (single-nucleotide polymorphisms and haplotypes) may strongly influence the occurrence of MPNs. In this context, the LNK inhibitory adaptor protein encoded by the LNK/SH2B adaptor protein 3 (SH2B3) gene is the target of several genetic variations, acquired or inherited in MPNs, lymphoid leukemia and nonmalignant hematological diseases, underlying its importance in these pathological processes. As LNK adaptor is a key regulator of normal hematopoiesis, understanding the consequences of LNK variants on its protein functions and on driver or other mutations could be helpful to correlate genotype and phenotype of patients and to develop therapeutic strategies to target this molecule. In this review we summarize the current knowledge of LNK function in normal hematopoiesis, the different SH2B3 mutations reported to date and discuss how these genetic variations may influence the development of hematological malignancies.
引用
- Maslah N, Cassinat B, Verger E, et al. The role of LNK/SH2B3 genetic alterations in myeloproliferative neoplasms and other hematological disorders. Leukemia. 2017. PMID: 28484264. doi:10.1038/leu.2017.139
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。